Analysis from DelveInsight predicts that the market for treating Acute-on-Chronic Liver Failure (ACLF) will expand considerably through 2034, driven by a growing chronic‑liver disease population and the emergence of novel therapies targeting this critical condition.
According to the report, the United States currently represents the largest share of the “7MM” ACLF market (US, EU‑4, UK, Japan). The rising prevalence of chronic liver disorders—including cirrhosis, alcoholic liver disease, viral hepatitis, and metabolic‑associated liver disease—is increasing the number of patients at risk for ACLF, thereby expanding the potential treatment pool.
A key factor in the projected growth is the active development of several investigational drugs, including VS-01, G1090N (reformulated NTZ), SRT-015, CLM-022, YAQ005, and ALBUTINE (albumin 5 %) among others. These therapies aim to address various aspects of ACLF pathophysiology—from toxicity/metabolite clearance to organ support and inflammation—rather than relying solely on supportive care or transplantation.
Because ACLF currently lacks approved disease‑modifying treatments—and standard care remains mostly supportive—the arrival of effective, targeted therapies could redefine the care paradigm, improve survival and outcomes, and substantially expand market demand.
